AGLITTI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 529
EU - Europa 168
AS - Asia 97
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 797
Nazione #
US - Stati Uniti d'America 527
IT - Italia 64
CN - Cina 53
DE - Germania 28
IE - Irlanda 20
SG - Singapore 17
TR - Turchia 17
GB - Regno Unito 15
RU - Federazione Russa 11
DK - Danimarca 9
SE - Svezia 8
UA - Ucraina 7
IN - India 3
EU - Europa 2
FR - Francia 2
HK - Hong Kong 2
MY - Malesia 2
RO - Romania 2
TW - Taiwan 2
AU - Australia 1
ES - Italia 1
HN - Honduras 1
MX - Messico 1
NO - Norvegia 1
PH - Filippine 1
Totale 797
Città #
Chandler 94
Princeton 70
Ann Arbor 69
Ashburn 60
Woodbridge 31
Jacksonville 26
Dublin 20
Izmir 17
Beijing 16
Andover 15
Washington 14
Nürnberg 13
Wilmington 12
Houston 8
Nanjing 8
Singapore 8
Naples 7
Salerno 7
Fairfield 6
Los Angeles 5
Norwalk 5
Redwood City 5
San Giorgio A Cremano 5
Dallas 4
Frederiksberg 4
Guangzhou 4
Hebei 4
Jinan 4
Pontecagnano 4
Saint Petersburg 4
Bolzano 3
Falls Church 3
Latina 3
Nanchang 3
Rome 3
Boardman 2
Haikou 2
Hong Kong 2
Kuala Lumpur 2
London 2
Mercato San Severino 2
Monte San Giovanni Campano 2
Pellezzano 2
San Diego 2
Seattle 2
Shanghai 2
Taoyuan District 2
Tianjin 2
Aachen 1
Aversa 1
Bengaluru 1
Cambridge 1
Changsha 1
Chennai 1
Dearborn 1
Esslingen am Neckar 1
Gunzenhausen 1
Islington 1
Leawood 1
Melbourne 1
Mexico 1
Miami 1
Oslo 1
Pozzuoli 1
Reggio Calabria 1
San Fernando 1
Shenyang 1
Tegucigalpa 1
Walnut 1
Weimar 1
Totale 612
Nome #
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 93
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 87
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 83
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 54
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 53
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 51
The diagnostic conundrum in non-alcoholic fatty liver disease 49
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 41
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 40
Viral hepatitis: Milestones, unresolved issues, and future goals 40
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 36
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 35
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection 35
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 33
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 32
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 31
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 31
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 27
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 2
Totale 853
Categoria #
all - tutte 3.777
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.777


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202057 0 0 3 2 0 2 9 4 0 18 9 10
2020/2021100 15 1 4 5 5 8 9 8 13 6 21 5
2021/2022129 4 2 5 0 6 2 4 5 21 11 16 53
2022/2023190 19 14 23 17 16 48 0 16 18 2 12 5
2023/2024146 7 8 17 9 20 40 0 9 6 5 8 17
2024/202511 2 8 1 0 0 0 0 0 0 0 0 0
Totale 853